Alzheimer's Disease Trial, Not Yet Recruiting NCT06677632 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT06677632
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been clinically diagnosed with Alzheimer's Disease.
  • People who are between 18 and 80 years old.
  • People who have signed a form giving their informed consent to take part.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have other conditions affecting the brain or nervous system.
  • People who have blood clotting disorders, or who are taking blood-thinning medications.
  • People who have skin conditions or diseases affecting the body's connective tissues.
  • People who have other physical health conditions, mental health conditions, or abnormal test results that could affect their ability to participate or affect the study results.
  • People who are unable to give informed consent.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Claudio Grassi, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phone: +390630154966

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
11 November 2024
Est. completion
31 August 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Differences in zDHHC mRNA and protein expression levels between Alzheimer's disease (AD) models and control samples; Change in AD-associated deficits following zDHHC7 downregulation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov